Premium
Sequential early cognitive changes sensitive to rising beta‐amyloid and tau pathology in preclinical AD
Author(s) -
Farrell Michelle E.,
Papp Kate V.,
Buckley Rachel F.,
Jacobs Heidi I.L.,
Schultz Aaron P,
Properzi Michael J,
Vannini Patrizia,
Hanseeuw Bernard,
Rentz Dorene M.,
Johnson Keith A.,
Sperling Reisa A.
Publication year - 2021
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.056315
Subject(s) - entorhinal cortex , psychology , cognitive decline , cognition , neuroscience , medicine , hippocampus , disease , dementia
Background AD clinical trials are increasingly looking towards intervention at the earliest stage of preclinical AD, when beta‐amyloid (Aβ) is emerging and tau pathology remains restricted to the MTL. While some evidence suggests subtle cognitive changes start at this early stage, it is unclear what cognitive measures may be most sensitive to emerging pathology and whether they reflect Aβ, tau or both. Method 143 clinically‐normal adults with longitudinal PIB‐PET, FTP‐PET and cognitive data (median follow‐up: 7.68(1.17) years) were included from the Harvard Aging Brain Study (HABS). Analyses focused first on those initially PIB‐ (